Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News LadRx Corp LADX

Healthcare Biotechnology
LadRx Corp is a biopharmaceutical research and development company specializing in oncology. The Company focuses on the discovery, research and clinical development of anti-cancer drug candidates that employ technologies that target chemotherapeutic drugs to solid tumors and reduce off-target toxicities. The Company’s linker activated drug release (LADR) technology platform consists of an... see more

Recent & Breaking News (OTCQB:LADX)

CytRx Corporation Announces $8.1 Million Registered Direct Offering of Common Stock

PR Newswire December 13, 2016

Watch These 4 Huge Put Purchases In Tuesday Trade

Benzinga.com  December 13, 2016

Leading Sarcoma Expert Dr. Earl W. Brien Joins CytRx Board of Directors

PR Newswire December 2, 2016

CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

Benzinga.com  November 29, 2016

CytRx Reports Statistically Significant Updated Results from Pivotal Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcomas

PR Newswire November 29, 2016

CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial at the 2016 CTOS Annual Meeting

PR Newswire November 11, 2016

CytRx Reports Third Quarter 2016 Financial Results

PR Newswire November 9, 2016

Research Reports Coverage on Biotech Stocks -- Tesaro, Aralez Pharma, Rexahn Pharma, and CytRx

PR Newswire November 7, 2016

CytRx Presents Interim Results from On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Clinical Trial at ESMO 2016 Congress

PR Newswire October 10, 2016

24-Hour Deadline Alert: Law Offices of Howard G. Smith Reminds Investors of the Upcoming September 23rd Deadline in the Class Action Lawsuit Against CytRx Corporation

Business Wire September 22, 2016

DEADLINE TOMORROW: Levi & Korsinsky, LLP Reminds Shareholders of CytRx Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 23, 2016 - CYTR

PR Newswire September 22, 2016

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline

PR Newswire September 20, 2016

GPM Reminds Investors of the September 23rd Deadline in the Class Action Lawsuit Against CytRx Corporation and Encourages Investors to Contact the Firm

Business Wire September 19, 2016

CYTR UPCOMING DEADLINE: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016

GlobeNewswire September 19, 2016

SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In CytRx Corporation To Contact The Firm Before Imminent Lead Plaintiff Deadline

GlobeNewswire September 16, 2016

Brower Piven Alerts Shareholders of September 23, 2016 Deadline in Class Action Lawsuit and Encourages Those With Losses in Excess of $100,000 From Investment in CytRx Corporation to Contact the Firm - CYTR

GlobeNewswire September 15, 2016

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of CytRx Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 23, 2016 – CYTR

GlobeNewswire September 13, 2016

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in CytRx Corporation of Class Action Lawsuit and Upcoming Deadline – CYTR

GlobeNewswire September 12, 2016

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of CytRx Corporation of a Class Action Lawsuit and a Lead Plaintiff Deadline of September 23, 2016 – CYTR

Business Wire September 9, 2016

CYTR SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving CytRx Corporation and a Lead Plaintiff Deadline of September 23, 2016

Business Wire September 6, 2016